Literature DB >> 12007911

Androgen insufficiency in women: summary of critical issues.

Glenn D Braunstein1.   

Abstract

Critical issues concerning the role of androgens in the physical, sexual, and emotional health of women include the following:1. Which androgens best reflect the androgen status of women? 2. What form of T should be measured and how? 3. Do T levels fall after menopause? 4. What effect does oophorectomy have on T levels? 5. What is the relationship between T and sexual dysfunction? 6. What constitutes androgen insufficiency syndrome? 7. What conditions are associated with androgen insufficiency? 8. How should a patient with suspected androgen insufficiency be evaluated? 9. Does androgen replacement therapy improve sexual dysfunction? 10. Do androgens enhance the quality of life? 11. Is estrogen and androgen therapy superior to estrogen therapy alone for low bone mineral density? 12. What are the indications for androgen replacement therapy? 13. What is the best means for delivery of androgen therapy? 14. How should androgen replacement therapy be monitored? Based on our current knowledge, it is clear that some women develop symptomatic androgen insufficiency and that androgen replacement therapy has a beneficial effect on libido, sexual satisfaction, quality of life, and bone mineralization. Androgen replacement therapy should be given the same consideration that we give estrogen replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12007911     DOI: 10.1016/s0015-0282(02)02962-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Aetiology, diagnosis, and management of hypopituitarism in adult life.

Authors:  V K B Prabhakar; S M Shalet
Journal:  Postgrad Med J       Date:  2006-04       Impact factor: 2.401

Review 2.  Female sexual dysfunction.

Authors:  Erdogan Aslan; Michelle Fynes
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-11-01

3.  A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.

Authors:  D A Papanicolaou; S N Ather; H Zhu; Y Zhou; J Lutkiewicz; B B Scott; J Chandler
Journal:  J Nutr Health Aging       Date:  2013       Impact factor: 4.075

4.  Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation.

Authors:  Javier I Torréns; Kim Sutton-Tyrrell; Xinhua Zhao; Karen Matthews; Sarah Brockwell; Maryfran Sowers; Nanette Santoro
Journal:  Menopause       Date:  2009 Mar-Apr       Impact factor: 2.953

5.  The influence of metabolic factors for nonalcoholic Fatty liver disease in women.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Seon Hee Lim; Jong In Yang; Young Sun Kim; Sun Young Yang; Min-Sun Kwak; Joo Sung Kim; Sang-Heon Cho
Journal:  Biomed Res Int       Date:  2015-04-20       Impact factor: 3.411

Review 6.  Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence.

Authors:  Maria Garefalakis; Martha Hickey
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

7.  Visualising androgen receptor activity in male and female mice.

Authors:  D Alwyn Dart; Jonathan Waxman; Eric O Aboagye; Charlotte L Bevan
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

8.  Bioavailable testosterone is independently associated with Fatty Liver Index in postmenopausal women.

Authors:  Aleksandra Klisic; Nebojsa Kavaric; Milovan Jovanovic; Ivan Soldatovic; Najdana Gligorovic-Barhanovic; Jelena Kotur-Stevuljevic
Journal:  Arch Med Sci       Date:  2017-07-19       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.